Indications:

• Improvement of physical exercise capacity in patients with Coronary Artery Disease NYHA 2-3

• Chronic Heart Failure (in research)

Contraindications:

• Acute inflammatory diseases
• Acute somatic diseases 
• Congenital heart and major vessels defects
• Severe chronic obstructive pulmonary disease (COPD)
• Acute cerebro-vascular events (<6 months prior to IHT)
• Acute forms of ischaemic heart disease (acute coronary syndrome, myocardial infarction
•  Heart failure III-IV clas
• Chronic obstructive pulmonary disease
• Bronchial asthma with significant respiratory distress (SpO₂ <90%)
• Reanl failure
• Oncological diseases
• Systemic diseases
• Severe psychic diseases
• Individual intolerance to oxygen defficacy

Physiological effects:

• Improves the microcirculation [Belyavskiy et al., Bobyleva et al., Ischuk et al., Townsend et al.]

• Reduces endothelial dysfunction [Chiu et al. , Elchaninova et al., Haider et al., Manukhina et al.]

• Decreases the blood pressure [Ainslie et al. , Bailey et al. , Elchaninova et al., Lyamina et al. , Manukhina et al., Shatilo et al.]

• Increases myocardium and brain resistance to acute ischaemia (precondition-like effect) [Bulgak et al., Zhua et al.]

• Reduction in the negative consequences of systemic oxidative stress [Arkhipenko et al., Borukaeva et al., Elchaninova et al.]

Clinical Effects:

• Increases time to fatigue

• Increases physical endurance

• Increases VO₂ peak

• Increases %VO₂ max

• Increases Anaerobic threshold

• Lowers incidence of angina as a reason to stop treadmill run

• Lowers incidence of ST depression as a reason to stop treadmill run